- Home
- HCC vs DYN Comparison
HCC vs DYN Comparison
Compare HCC & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCC
- DYN
- Stock Information
- Founded
- HCC 2015
- DYN 1984
- Country
- HCC United States
- DYN United States
- Employees
- HCC N/A
- DYN N/A
- Industry
- HCC Coal Mining
- DYN Medicinal Chemicals and Botanical Products
- Sector
- HCC Energy
- DYN Health Care
- Exchange
- HCC Nasdaq
- DYN Nasdaq
- Market Cap
- HCC 2.8B
- DYN 2.6B
- IPO Year
- HCC 2017
- DYN 2020
- Fundamental
- Price
- HCC $46.22
- DYN $14.01
- Analyst Decision
- HCC Strong Buy
- DYN Strong Buy
- Analyst Count
- HCC 5
- DYN 10
- Target Price
- HCC $75.00
- DYN $50.78
- AVG Volume (30 Days)
- HCC 755.0K
- DYN 2.1M
- Earning Date
- HCC 02-13-2025
- DYN 03-04-2025
- Dividend Yield
- HCC 0.69%
- DYN N/A
- EPS Growth
- HCC N/A
- DYN N/A
- EPS
- HCC 4.79
- DYN N/A
- Revenue
- HCC $1,525,220,000.00
- DYN N/A
- Revenue This Year
- HCC $4.64
- DYN N/A
- Revenue Next Year
- HCC $11.97
- DYN N/A
- P/E Ratio
- HCC $9.65
- DYN N/A
- Revenue Growth
- HCC N/A
- DYN N/A
- 52 Week Low
- HCC $45.94
- DYN $13.07
- 52 Week High
- HCC $75.53
- DYN $47.45
- Technical
- Relative Strength Index (RSI)
- HCC 30.42
- DYN 37.85
- Support Level
- HCC $52.27
- DYN $13.59
- Resistance Level
- HCC $50.81
- DYN $14.50
- Average True Range (ATR)
- HCC 2.19
- DYN 0.98
- MACD
- HCC -0.48
- DYN 0.32
- Stochastic Oscillator
- HCC 2.99
- DYN 22.90
About HCC Warrior Met Coal Inc.
Warrior Met Coal Inc is a U.S based company. It produces and exports of met coal that operates underground mines in Alabama. The company sells to steels manufacturers in Europe, Asia, and South America. Its mining operations consist of two underground met coal mines in Southern Appalachia's coal seam and other surface met and thermal coal mines. The Company generates ancillary revenues from the sale of natural gas extracted as a byproduct from the underground coal mines and royalty revenues from leased properties.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial.